본문 바로가기
KERD
논문KCI 등재

우리나라의 현행 의약품분류체계에 대한 고찰 및 개선 방안

Current Drug Classification System in Korea and Its Improvement

0

조회

0

다운로드

2

인용

0

참고문헌

주제분류약학

초록

Abstract

Appropriate drug classification is important for rational drug consumption. This study was conducted to evaluate the appropriateness of current drug classification system and suggest possible ways for improving the system. Nonprescription drug market has been decreased. Since total 27,962 products had been classified (prescription 17,187 vs. nonprescription 10,775 products, 61.5% vs. 38.5%) in July 2000 for implementing separation of drug prescribing and dispensing system, there are no classification changes. Reclassification is not motivated by product holder and regulatory system did not lead classification change either. Consumers’ ease access to some nonprescription drugs is demanded. But point of public awareness and cultural and health environmental views, safe drug use rather than advantages from broad supply of nonprescription drugs is more critical. We concluded that current 2-categorized (prescription and nonprescription) drug classification system is appropriate, and addition of general sale category should be approached carefully with long term preparations such as establishment of better nonprescription drug consuming infrastructure by public information provision and education for improving public medicinal knowledge and strengthening self medication guidance, and review of current classification status of marketed drugs and switching possibilities. For systemizing and encouraging reclassification, introduction of regulatory renewal system as a continuous reevaluation program which is the best way to review appropriateness of drug classification as well as provision of detailed guidance for industry including policy, requirement and process for reclassification application, are necessary.

참고문헌 (11)

  1. 전문-일반의약품 분류결과 발표, "보건복지부 보도자료", pp.31~
  2. "의약품분류기준에관한규정" (2000)
  3. "Pharmaceutical Administration and Regulations in Japan"
  4. MHRA Guidance Note 11, "Changing the legal classification in the United Kingdomof a medicine for human use"
  5. uk, "Licensing of Medicines" (2004)
  6. uk, "Article on new reclassification process in MAIL 130", 20020304, ~
  7. Andersson F, "The costs and benefits ofswitching a drug from prescription-only to over-the-counterstatus a review of methodological issues and current evidence", pharmacoeco(mics), pp.388~96 (1992)
  8. Lowe NK, "Over-the-counter medicationsand self-care", 24(12), pp.34~44 (1999)
  9. What We Do, "US FDA CDER Division of OTC Office of Drug EvaluationV Division of OTC - Who We Are"
  10. 21 CFR Sec, "14 Additional criteria and proceduresfor classifying OTC drugs as generally recognized as safeand effective and not misbranded", pp.21~
  11. "A draft guidance for industry for TEA applications"

관련 논문AI추천

이 간행물의 다른 논문 (10건)